7-Day Rally Sends Corcept Therapeutics Stock Up 24%
Corcept Therapeutics (CORT) – a developer and marketer of drugs for severe metabolic disorders – hit a 7-day winning streak, with cumulative gains over this period amounting to 24%. The company’s market cap has surged by about $1.4 Bil over the last 7 days and currently stands at $7.1 Bil.
Is this an opportunity or a trap? There is a near-equal mix of good and bad in CORT stock given its overall Moderate operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Unattractive (For details, see Buy or Sell CORT).
But here is the interesting part. You are reading about this 24% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio is based on an architecture that includes such signals.
Returns vs S&P 500
- CSCO Stock: Two Signals Pointing The Same Way
- Decoding AVGO Stock’s Premium Valuation
- What Could Push NVDA Stock Higher From Here?
- Cash Machine Trading Cheap – Inspire Medical Systems Stock Set to Run?
- Five-Year Tally: AT&T Stock Delivers $58 Bil Gain
- Years of Rewards: $43 Bil From Caterpillar Stock
The following table summarizes the return for CORT stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CORT | S&P 500 |
|---|---|---|
| 1D | 2.6% | 0.6% |
| 7D (Current Streak) | 24.1% | 2.2% |
| 1M (21D) | 46.7% | 6.0% |
| 3M (63D) | 91.1% | 9.5% |
| YTD 2026 | 96.5% | 10.5% |
| 2025 | -30.9% | 16.4% |
| 2024 | 55.1% | 23.3% |
| 2023 | 59.9% | 24.2% |
However, big gains can follow sharp reversals – but how has CORT behaved after prior drops? See CORT Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 66 S&P constituents with 3 days or more of consecutive gains and 80 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 21 | 50 |
| 4D | 10 | 19 |
| 5D | 1 | 7 |
| 6D | 30 | 3 |
| 7D or more | 4 | 1 |
| Total >=3 D | 66 | 80 |
Key Financials for Corcept Therapeutics (CORT)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $675.0 Mil | $761.4 Mil |
| Operating Income | $137.0 Mil | $44.8 Mil |
| Net Income | $141.2 Mil | $99.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $202.1 Mil | $164.9 Mil |
| Operating Income | $4.5 Mil | $-49.6 Mil |
| Net Income | $24.3 Mil | $-31.8 Mil |
While CORT stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.